Barchart on MSN2d
Is Agilent Technologies Stock Outperforming the Nasdaq?
Valued at a market cap of $34.5 billion, Agilent Technologies, Inc. (A) is an original equipment manufacturer of a ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Chromatography Online9d
Agilent Reports Financial Results From Q1 of 2025
The company reported $1.68 billion in revenue at a 25.1% operating margin across its businesses in America, Europe, and Asia.
Yahoo Finance22d
Agilent Reports First-Quarter Fiscal Year 2025 Financial Results
Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core (1) basis compared with the first quarter of 2024. GAAP net income of ...
Morningstar10d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...
Business Wire10d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE ... When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with ...